Kymera Therapeutics (NASDAQ: KYMR) reported insider transactions by Chief Operating Officer Jeremy G. Chadwick, who sold a total of 22,240 shares of the companys common stock on March 31 and April 1, 2026. The transactions generated approximately $1.9 million in proceeds, with per-share sale prices ranging from $85.3792 to $86.05.
The filings show the sales were carried out under a pre-arranged Rule 10b5-1 trading plan, according to a Form 4 submitted to the Securities and Exchange Commission. The companys stock has experienced a notable advance over the last year - delivering a 237% return - and was trading at $84.93 at the time the information was reported.
On the same dates as the stock sales, Chadwick exercised stock options to acquire 22,240 shares of Kymera common stock at an exercise price of $29.64 per share. The aggregate value associated with that option exercise was reported as $659,193. After completing the exercises and the subsequent sales, Chadwick is listed as directly owning 61,202 shares of Kymera Therapeutics.
Investment-analysis commentary noted in the disclosure indicates that, based on InvestingPro assessments, the shares presently appear overvalued relative to their Fair Value. That valuation view was cited as a possible factor influencing the decision to realize gains through the Rule 10b5-1 plan.
Analyst activity and corporate updates accompanied the disclosure of the insider transactions. Kymera announced that data from its KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis will be presented at the American Academy of Dermatology 2026 Annual Meeting on March 28, 2026, in Denver, Colorado.
Several brokerages have recently adjusted price targets and maintained favorable ratings. Stephens raised its target to $100 while keeping an Overweight rating after the companys fourth-quarter and full-year 2025 financial results and business update. Morgan Stanley moved its target to $123 from $127 and retained an Overweight rating, pointing to market opportunities in type 2 diseases and progress across Kymeras degrader pipeline. RBC Capital lifted its target to $108 from $103 and kept an Outperform rating, noting a potentially quieter year as phase II development for KT-621 in atopic dermatitis and asthma continues.
For investors seeking additional context on insider activity and equity analysis, InvestingPro is referenced as providing over 10 additional ProTips for KYMR and detailed Pro Research Reports covering more than 1,400 U.S. equities.
What this means - The reported transactions combine option exercises with share sales undertaken under a pre-set trading plan, while the company remains the focus of analyst attention and near-term clinical data presentations.